Nutra Pharma Corp (NPHC)
NPHC is quoted over the counter, not listed on an exchange. Nutra Pharma Corp files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | NPHC, quoted over the counter |
| SEC CIK | 0001119643 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Medicinal Chemicals & Botanical Products |
| Business address | Boca Raton, FL |
| Incorporated in | CA |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations." | 10-Q 2026-08-19 |
| Cash and burn | $22K cash; operating cash flow -$262K a quarter. | Report 2026-06-30 |
| Shares outstanding | 7,159,727,214 (2026-08-19); 7,099,727,214 a year earlier. | Cover page 2026-08-19 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Astra Audit & Advisory, LLC, Tampa, Florida, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-09-03 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $34K | -$3.9M | -$251K | Not filed | $12.6M | $161K | 10-Q 2026-08-19 |
| Q1 2026 2026-03-31 | $27K | -$460K | -$328K | $22K | $10.0M | $211K | 10-Q 2026-05-29 |
| Q4 2025 2025-12-31 | $29K | -$489K | -$220K | $12K | $9.8M | $258K | 10-K 2026-05-20 |
| Q3 2025 2025-09-30 | $70K | -$524K | -$251K | $4K | $9.7M | $311K | 10-Q 2026-04-06 |
| Q2 2025 2025-06-30 | $85K | $370K | -$288K | $79K | $9.5M | $315K | 10-Q 2026-08-19 |
| Q1 2025 2025-03-31 | $74K | -$1.4M | -$405K | $14K | $9.1M | $283K | 10-Q 2026-05-29 |
| Q4 2024 2024-12-31 | $82K | -$231K | -$178K | $36K | $8.6M | $246K | 10-K 2026-05-20 |
| Q3 2024 2024-09-30 | $75K | -$261K | $19K | $0 | $8.4M | $211K | 10-Q 2026-04-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1/A | 2011-01-06 |
| Latest annual report | 10-K | 2026-05-20 |
| Latest quarterly / interim | 10-Q | 2026-08-19 |
| Latest current report | 8-K | 2026-09-02 |
| Latest proxy | DEF 14A | 2015-03-17 |
Source: SEC EDGAR submissions feed, 350 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier